1455P A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
J. Feng(Hangzhou First People's Hospital), Liang Shi(Shanghai Jiao Tong University), Junying Xu(Wuxi People's Hospital), Zhengxiang Han(Xuzhou Medical College), Jingfeng Mei(Jiangsu Cancer Hospital), Qingqing Wang(Nantong University), Bo Shen(Jiangsu Cancer Hospital), Yuan Wu(Jiangsu Cancer Hospital), Guo-Wen Ling, Yong Mao(Jiangnan University), Maohuai Cai(Yancheng Second People's Hospital), Yonggong Yang(Nanjing Drum Tower Hospital)
Cited by 0
Related Papers
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268